Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Emergent BioSolutions Inc.NYSE: EBS
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 7.4% from a year ago
Total assets stood at $1.32B at the end of Q1 FY2026, down 7.4% from a year earlier and up 0.1% from the prior quarter. Over 3 fiscal years it compounded at -25.3% a year.
Context
- Total assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -7.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.32B USD
- Year-over-year change
- -5.1%
- 4-year CAGR
- -18.3%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.32B | -5.1% |
| FY2024 | 2024-12-31 | 1.39B | -23.8% |
| FY2023 | 2023-12-31 | 1.82B | -42.4% |
| FY2022 | 2022-12-31 | 3.17B | +7.1% |
| FY2021 | 2021-12-31 | 2.96B | — |
Total Assets vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of -7.4% is the 9th highest of 11, against a peer median of +33.8%.
- Over three fiscal years its annual growth of -25.3% compares with a peer median of +7.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $1.32B USD | -7.4% | -25.3% | |
| Mar 2026 | CA$1.31B CAD | +0.1% | -5.0% | |
| Mar 2026 | $531.74M USD | +66.6% | +2.2% | |
| Mar 2026 | $530.65M USD | +29.5% | +35.2% | |
| Mar 2026 | $519.99M USD | +11.3% | +10.0% | |
| Mar 2026 | $504.61M USD | +186.8% | +56.4% | |
| Mar 2026 | $462.53M USD | +42.7% | +23.4% | |
| Mar 2026 | $349.89M USD | -29.4% | -24.5% | |
| Mar 2026 | $253.2M USD | +326.0% | +1.4% | |
| Mar 2026 | $219.39M USD | -11.2% | +4.0% | |
| Mar 2026 | $141.13M USD | +38.0% | +41.1% | |
| Peer median (excluding EBS) | — | +33.8% | +7.0% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 576.3M | 642.6M | 111.7M | 99.5M | 205.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 278.9M | 159.2M | 191M | 154.5M | 84.2M |
| Inventory | 344.5M | 350.7M | 328.9M | 311.7M | 343.4M |
| Other Current Assets | 70.2M | 57.9M | 47.9M | 33M | 29.5M |
| Total Current Assets | 1.27B | 1.21B | 679.5M | 598.7M | 662.5M |
| Property, Plant & Equipment (Net) | 828.4M | 837M | 399M | 270.6M | 205.4M |
| Goodwill | 224.9M | 218.2M | 0 | 0 | 0 |
| Intangible Assets | 604.6M | 728.8M | 566.6M | 501.5M | 436.5M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 29.9M | 171.9M | 178.1M | 18.9M | 14.2M |
| Total Non-current Assets | 1.69B | 1.96B | 1.14B | 791M | 656.1M |
| Total Assets | 2.96B | 3.17B | 1.82B | 1.39B | 1.32B |
| Account Payables | 128.9M | 103.5M | 112.2M | 60.9M | 55.6M |
| Short-term Debt | 37.4M | 963.1M | 413.7M | 2.7M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 11.7M | 26.4M | 0 | 0 | 0 |
| Other Current Liabilities | 107.3M | 48.6M | 106.8M | 81.1M | 76.6M |
| Total Current Liabilities | 374M | 1.23B | 651.3M | 162.4M | 132.2M |
| Long-term Debt | 809.4M | 448.5M | 446.5M | 663.7M | 572.1M |
| Deferred Tax Liabilities | 93.3M | 59.7M | 47.2M | 41.7M | 37.8M |
| Deferred Revenue (Non-current) | 4.7M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 40.6M | 26.7M | 28.9M | 29.4M | 53.9M |
| Total Non-current Liabilities | 972.2M | 549.7M | 522.6M | 744.5M | 663.8M |
| Total Liabilities | 1.35B | 1.78B | 1.17B | 906.9M | 796M |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 950.3M | 738.7M | (21.8M) | (212.4M) | (159.8M) |
| Accumulated OCI | (16.1M) | 3.1M | (5.7M) | (5.2M) | (7.5M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.61B | 1.39B | 649.3M | 482.8M | 522.6M |
| Total Debt | 871M | 1.43B | 860.2M | 676.1M | 572.1M |
| Net Debt | 294.7M | 783.8M | 748.5M | 576.6M | 366.7M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.